Robert W. Baird Lowers Phreesia (NYSE:PHR) Price Target to $30.00

Phreesia (NYSE:PHR - Free Report) had its target price trimmed by Robert W. Baird from $34.00 to $30.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

PHR has been the topic of several other research reports. JPMorgan Chase & Co. raised their price target on Phreesia from $27.00 to $28.00 and gave the company an "overweight" rating in a research note on Monday, September 9th. Needham & Company LLC reissued a "buy" rating and set a $29.00 target price on shares of Phreesia in a research report on Tuesday. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $34.00 price target on shares of Phreesia in a research report on Thursday, September 5th. DA Davidson reissued a "buy" rating and set a $32.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Finally, Truist Financial upped their target price on Phreesia from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, September 6th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.33.

Phreesia Trading Up 2.7 %

Phreesia stock traded up $0.64 during trading hours on Wednesday, hitting $24.78. The company had a trading volume of 905,105 shares, compared to its average volume of 450,535. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The firm has a market cap of $1.43 billion, a P/E ratio of -13.91 and a beta of 0.98. The company has a 50-day moving average price of $20.29 and a two-hundred day moving average price of $21.76. Phreesia has a 1 year low of $17.07 and a 1 year high of $29.16.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. Phreesia's quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.58) earnings per share. On average, sell-side analysts anticipate that Phreesia will post -1.23 earnings per share for the current year.

Insider Transactions at Phreesia

In other Phreesia news, Director Michael Weintraub sold 15,152 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $21.01, for a total transaction of $318,343.52. Following the transaction, the director now owns 242,827 shares in the company, valued at approximately $5,101,795.27. This represents a 5.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Amy Beth Vanduyn sold 25,447 shares of Phreesia stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $20.93, for a total transaction of $532,605.71. Following the sale, the senior vice president now owns 93,470 shares of the company's stock, valued at $1,956,327.10. The trade was a 21.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,569 shares of company stock valued at $1,123,014 in the last quarter. 5.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Phreesia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHR. Trust Point Inc. increased its holdings in shares of Phreesia by 3.5% in the third quarter. Trust Point Inc. now owns 17,887 shares of the company's stock valued at $408,000 after purchasing an additional 607 shares during the period. Ensign Peak Advisors Inc increased its holdings in Phreesia by 3.2% in the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company's stock worth $477,000 after buying an additional 700 shares during the period. Rhumbline Advisers increased its holdings in Phreesia by 1.0% in the 2nd quarter. Rhumbline Advisers now owns 82,136 shares of the company's stock worth $1,741,000 after buying an additional 853 shares during the period. The Manufacturers Life Insurance Company raised its position in Phreesia by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company's stock worth $637,000 after buying an additional 905 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Phreesia by 3.8% during the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company's stock valued at $701,000 after acquiring an additional 1,120 shares during the period. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.